Home › NDC Lookup › Ingredients › Ammonium Lactate › 45802-0419-54
🧴image loading
(from DailyMed)

Ammonium Lactate 12 g/100g Lotion, 225 g — NDC 45802-419-54 (Billing 45802-0419-54)

by Padagis Israel Pharmaceuticals Ltd · 225 g in 1 BOTTLE, PLASTIC

This is a package of 225 g of Ammonium Lactate 12 g/100g Lotion from Padagis Israel Pharmaceuticals Ltd, marketed since Jun 2006 and currently FDA-listed; retail pharmacies pay about $0.0732 per g (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 45802-0419-54
🏷️ FDA NDC (as labeled) 45802-419-54 billing pads the product segment with a zero
This package
Contains225 g Cost per g$0.0732 NADAC Per package$16.47 / 225 g Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.0667/unit · Part D plans $0.0857/unit — full pricing hub ↓
Main listing for product 45802-419 · Also comes in: 400 g 45802-419-26
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Aug 6, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 45802-419-54 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
45802 labeler · 419 product · 54 package
Package marketed since
Jun 20, 2006
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
225 g per package
Barcode (UPC-A, from the NDC)
3 4580241954 5
Medicaid fills, this package
47,863 prescriptions in the last four reported quarters
FDA record last changed
Aug 6, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 45802-419-54
Product NDC 45802-419
11-digit billing NDC 45802041954
NCPDP billing unit GM — per gram (weight)
RxCUI 197362
UNII 67M901L9NQ
Application # ANDA075570
SPL Set ID dc3a6462-0f2c-4306-b5ef-c7b47395e959
Established class (EPC) alpha-Hydroxy Acid
Chemical class Hydroxy Acids
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2006-06-20
Route TOPICAL
Dosage form LOTION
Substance AMMONIUM LACTATE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 005826
GCN 20941
HICL code 015560
Ingredient (HICL) Ammonium Lactate
HIC1 code L
Therapeutic class — broad (HIC1) Skin/Subcutaneous Tissue
HIC2 code L2
Therapeutic class — intermediate (HIC2) Emollients
HIC3 code L2A
Therapeutic class — specific (HIC3) Emollients
AHFS code 84:24.04.00
AHFS class Basic Lotions And Liniments
FDB label name AMMONIUM LACTATE 12% LOTION
FDB brand name Ammonium Lactate
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 005826
  • GCN: 20941
  • HICL (First Databank): 015560
  • AHFS class code: 84:24.04.00
  • RxCUI (RxNorm): 197362
Why two NDCs? The FDA registers this code as 45802-419-54 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 45802-0419-54. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Organic acids class.

Drug family (ATC) Organic acids
How it works Acidifying Activity
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name AMMONIUM LACTATE 12% LOTION Ingredient Ammonium Lactate

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.073 $16.47 / 225 g
Medicaid paysCMS SDUD · 12 mo $0.0667 $15.01 / 225 g
Medicare drug plans payPart D · Q2 2026 $0.0857 $19.28 / 225 g
NADAC price history (per g) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.078 $0.063
▼ Down 3% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
45802-0419-26 45802-419-26 400 g in 1 BOTTLE, PLASTIC $0.0724 / g $28.96 2006-06-20 — Active
45802-0419-54 You're viewing this Main listing 225 g in 1 BOTTLE, PLASTIC $0.0732 / g $16.48 2006-06-20 — Active

You're viewing the smallest of 2 pack sizes for this product.

In Medicaid, this is the most-dispensed pack of this product — about 52% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package contains 225 g — 225 g in 1 bottle, plastic.
How does this package differ from NDC 45802-0419-26?
Both are Ammonium Lactate 12 g/100g Lotion — the drug itself is identical. This page's package is the 225 g one, while NDC 45802-0419-26 is the 400 g package. Per-g NADAC also differs: $0.0732 here vs $0.0724 for the 400 g pack.
What NDC number is used to bill for this package of Ammonium Lactate 12 g/100g Lotion?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Ammonium Lactate 12 g/100g 45802-0493-26 Padagis 385 g $0.067 AB Availability likely save 9%
Ammonium Lactate 12 g/100gthis 45802-0419-54 Padagis 225 g $0.073 AB Availability likely —
Ammonium Lactate 120 mg/g 51672-1300-05 Sun 225 g $0.073 AB Availability likely —
Ammonium Lactate 120 mg/g 50090-6587-00 A-S 225 g — AB FDA listed —
Ammonium Lactate 12 g/100g 63629-8610-01 Bryant 225 g — AB FDA listed —
Ammonium Lactate 12 g/100g 63629-8611-01 Bryant 400 g — AB FDA listed —
Ammonium Lactate 12 g/100g 72162-1407-02 Bryant 225 g — AB FDA listed —
Ammonium Lactate 12 g/100g 63629-8609-01 Bryant 385 g — AB FDA listed —
Ammonium Lactate 12 g/100g 72162-1413-02 Bryant 2 tubes — AB FDA listed —
Ammonium Lactate 12 g/100g 63629-8608-01 Bryant 2 tubes — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2006
On the market since
Jun 2006
📍
2026
Currently FDA-listed
20 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 936JST6JCN
    Cetyl alcohol is a waxy, fatty substance derived from plant or animal sources. It acts as an emulsifier and thickener in medicines, helping blend oil and water components and giving products a smooth, creamy texture.
  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII 230OU9XXE4
    A waxy substance made from glycerin and stearic acid that acts as an emulsifier to blend oily and watery ingredients together. It also helps thicken and stabilize the medicine's texture.
  • UNII 6HQ855798J
    Laureth-4 is a synthetic detergent made from lauryl alcohol and ethylene oxide. It acts as an emulsifier and solubilizer, helping blend oil and water-based ingredients and improve how the body absorbs the active drug.
  • UNII N6K5787QVP
    Light mineral oil is a clear, odorless liquid derived from petroleum. In medicines, it acts as a lubricant and emollient to help the product spread smoothly and improve texture.
  • UNII 6M3P64V0NC
    A fine powder made from magnesium, aluminum, and silicon compounds. It absorbs moisture and helps keep medicine ingredients from clumping or separating, so the product stays stable and flows smoothly during manufacturing.
  • UNII O0GN6F9B2Y
    Methylcellulose is a thickening and binding ingredient made from cellulose, a plant fiber. It helps control how fast the medicine dissolves and gives tablets or capsules the right texture and consistency.
  • UNII A2I8C7HI9T
    Methylparaben is a preservative derived from benzoic acid that prevents growth of bacteria, fungi, and mold in medicines. It extends the product's shelf life and maintains safety during storage.
  • UNII YD01N1999R
    A waxy substance made from polyethylene glycol and stearic acid. It helps mix oil and water-based ingredients together and serves as an emulsifier and solubilizer in liquid and semi-solid medicines.
  • UNII 13A4J4NH9I
    A synthetic emulsifier derived from stearic acid and polyethylene glycol. It helps mix oil and water-based ingredients together in liquid medicines and creams to create a smooth, uniform product.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII Z8IX2SC1OH
    Propylparaben is a chemical preservative used to prevent bacterial and fungal growth in medicines and personal care products. It helps extend shelf life and maintain product safety during storage.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

13 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerPadagis Israel Pharmaceuticals Ltd
Application holderPADAGIS ISRAEL PHARMACEUTICALS LTD
FDA applicationANDA075570 (ANDA)
Labeler code45802
First marketedJun 2006
Product typeHuman Prescription Drug
Portfolio175 products on file

More NDCs from Padagis Israel Pharmaceuticals Ltd labeler code 45802

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 31 words ▾

INDICATIONS AND USAGE Ammonium Lactate Lotion, 12% is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris, and for the temporary relief of itching associated with these conditions.

⏱️ Dosage and Administration 23 words ▾

DOSAGE AND ADMINISTRATION Shake well. Apply to the affected areas and rub in thoroughly. Use twice daily or as directed by a physician.

⛔ Contraindications 21 words ▾

CONTRAINDICATIONS Ammonium Lactate Lotion, 12% is contraindicated in those patients with a history of hypersensitivity to any of the label ingredients.

⚠️ Warnings 41 words ▾

WARNING Sun exposure (natural or artificial sunlight) to areas of the skin treated with Ammonium Lactate Lotion, 12% should be minimized or avoided (see PRECAUTIONS ). The use of Ammonium Lactate Lotion, 12% should be discontinued if any hypersensitivity is observed.

🤒 Adverse Reactions 77 words ▾

ADVERSE REACTIONS The most frequent adverse experiences in patients with xerosis are transient stinging (1 in 30 patients), burning (1 in 30 patients), erythema (1 in 50 patients) and peeling (1 in 60 patients). Other adverse reactions which occur less frequently are irritation, eczema, petechiae, dryness, and hyperpigmentation. Due to the more severe initial skin conditions associated with ichthyosis, there was a higher incidence of transient stinging, burning and erythema (each occurring in 1 in 10 patients).

🤰 Pregnancy 101 words ▾

Pregnancy: Teratogenic effects: Pregnancy Category B – Animal reproduction studies have been performed in rats and rabbits at doses up to 0.7 and 1.5 times the human dose, respectively (600 mg/kg/day, corresponding to 3600 mg/m 2 /day in the rat and 7200 mg/m 2 /day in the rabbit) and have revealed no evidence of impaired fertility or harm to the fetus due to ammonium lactate formulations. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Ammonium Lactate Lotion, 12% should be used during pregnancy only if clearly needed.

🧒 Pediatric Use 22 words ▾

Pediatric Use - Safety and effectiveness of ammonium lactate have been demonstrated in infants and children. No unusual toxic effects were reported.

🧓 Geriatric Use 56 words ▾

Geriatric Use - Clinical studies of ammonium lactate lotion, 12% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious.

🆘 Overdosage 22 words ▾

OVERDOSAGE The oral administration of ammonium lactate to rats and mice showed this drug to be practically non-toxic (LD 50 >15 mL/kg).

🧬 Clinical Pharmacology 95 words ▾

CLINICAL PHARMACOLOGY Lactic acid is an alpha-hydroxy acid, it is a normal constituent of tissues and blood. The alpha-hydroxy acids (and their salts) may act as humectants when applied to the skin. This property may influence hydration of the stratum corneum.

In addition, lactic acid, when applied to the skin, may act to decrease corneocyte cohesion. The mechanism(s) by which this is accomplished is not yet known. An in vitro study of percutaneous absorption of ammonium lactate lotion, 12% using human cadaver skin indicates that approximately 5.8% of the material was absorbed after 68 hours.

📦 How Supplied / Storage and Handling 34 words ▾

HOW SUPPLIED Ammonium Lactate Lotion, 12% is available as follows: 225 g bottle (NDC 45802- 419 -54) 400 g bottle (NDC 45802- 419 -26) STORAGE Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].

📦 Storage and Handling 10 words ▾

STORAGE Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].

📋 Description 72 words ▾

DESCRIPTION *Ammonium Lactate Lotion, 12% specially formulates 12% lactic acid neutralized with ammonium hydroxide, as ammonium lactate to provide a lotion pH of 4.5 - 5.5. It also contains cetyl alcohol, fragrance, glycerin, glyceryl stearate, laureth-4, light mineral oil, magnesium aluminum silicate, methylcellulose, methylparaben, PEG-100 stearate, polyoxyl 40 stearate, propylene glycol, propylparaben, and purified water. Lactic acid is a racemic mixture of 2-hydroxypropanoic acid and has the following structural formula: structural formula

💬 Information for Patients 135 words ▾

Information for Patients Patients using Ammonium Lactate Lotion, 12% should receive the following information and instructions: 1. This medication is to be used as directed by the physician, and should not be used for any disorder other than for which it was prescribed. It is for external use only.

Avoid contact with eyes, lips, or mucous membranes. 2. Patients should minimize or avoid use of this product on areas of the skin that may be exposed to natural or artificial sunlight, including the face.

If sun exposure is unavoidable, clothing should be worn to protect the skin. 3. This medication may cause transient stinging or burning when applied to skin with fissures, erosions, or abrasions (for example, after shaving the legs).

4. If the skin condition worsens with treatment, the medication should be promptly discontinued.

⚠️ Precautions ~3 min read ▾

PRECAUTIONS General - For external use only. Stinging or burning may occur when applied to skin with fissures, erosions, or that is otherwise abraded (for example, after shaving the legs). Caution is advised when used on the face because of the potential for irritation.

The potential for post-inflammatory hypo- or hyperpigmentation has not been studied. Information for Patients Patients using Ammonium Lactate Lotion, 12% should receive the following information and instructions: 1. This medication is to be used as directed by the physician, and should not be used for any disorder other than for which it was prescribed.

It is for external use only. Avoid contact with eyes, lips, or mucous membranes. 2.

Patients should minimize or avoid use of this product on areas of the skin that may be exposed to natural or artificial sunlight, including the face. If sun exposure is unavoidable, clothing should be worn to protect the skin. 3.

This medication may cause transient stinging or burning when applied to skin with fissures, erosions, or abrasions (for example, after shaving the legs). 4. If the skin condition worsens with treatment, the medication should be promptly discontinued.

Carcinogenesis, Mutagenesis, Impairment of Fertility - The topical treatment of CD-1 mice with 12%, 21% or 30% ammonium lactate formulations for two-years did not produce a significant increase in dermal or systemic tumors in the absence of increased exposure to ultraviolet radiation. The maximum systemic exposure of the mice in this study was 0.7 times the maximum possible systemic exposure in humans. However, a long-term photocarcinogenicity study in hairless albino mice suggested that topically applied 12% ammonium lactate formulations enhanced the rate of ultraviolet light-induced skin tumor formation.

The mutagenic potential of ammonium lactate formulations was evaluated in the Ames assay and in the mouse in vivo micronucleus assay, both of which were negative. In dermal Segment I and III studies with ammonium lactate formulations there were no effects observed in fertility or pre- or postnatal development parameters in rats at dose levels of 300 mg/kg/day (1800 mg/m 2 /day), approximately 0.4 times the human topical dose. Pregnancy: Teratogenic effects: Pregnancy Category B – Animal reproduction studies have been performed in rats and rabbits at doses up to 0.7 and 1.5 times the human dose, respectively (600 mg/kg/day, corresponding to 3600 mg/m 2 /day in the rat and 7200 mg/m 2 /day in the rabbit) and have revealed no evidence of impaired fertility or harm to the fetus due to ammonium lactate formulations.

There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Ammonium Lactate Lotion, 12% should be used during pregnancy only if clearly needed. Nursing Mothers - Although lactic acid is a normal constituent of blood and tissues, it is not known to what extent this drug affects normal lactic acid levels in human milk.

Because many drugs are excreted in human milk, caution should be exercised when ammonium lactate is administered to a nursing woman. Pediatric Use - Safety and effectiveness of ammonium lactate have been demonstrated in infants and children. No unusual toxic effects were reported.

Geriatric Use - Clinical studies of ammonium lactate lotion, 12% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious.

🍼 Nursing Mothers 52 words ▾

Nursing Mothers - Although lactic acid is a normal constituent of blood and tissues, it is not known to what extent this drug affects normal lactic acid levels in human milk. Because many drugs are excreted in human milk, caution should be exercised when ammonium lactate is administered to a nursing woman.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 157 words ▾

Carcinogenesis, Mutagenesis, Impairment of Fertility - The topical treatment of CD-1 mice with 12%, 21% or 30% ammonium lactate formulations for two-years did not produce a significant increase in dermal or systemic tumors in the absence of increased exposure to ultraviolet radiation. The maximum systemic exposure of the mice in this study was 0.7 times the maximum possible systemic exposure in humans. However, a long-term photocarcinogenicity study in hairless albino mice suggested that topically applied 12% ammonium lactate formulations enhanced the rate of ultraviolet light-induced skin tumor formation.

The mutagenic potential of ammonium lactate formulations was evaluated in the Ames assay and in the mouse in vivo micronucleus assay, both of which were negative. In dermal Segment I and III studies with ammonium lactate formulations there were no effects observed in fertility or pre- or postnatal development parameters in rats at dose levels of 300 mg/kg/day (1800 mg/m 2 /day), approximately 0.4 times the human topical dose.

📄 Package Label / Principal Display Panel 113 words ▾

Principal Display Panel NDC 45802- 419 -26 Rx Only Ammonium Lactate Lotion, 12%* NET WT 400 g CONTAINS: *Ammonium lactate equivalent to 12% lactic acid, cetyl alcohol, fragrance, glycerin, glyceryl stearate, laureth-4, light mineral oil, magnesium aluminum silicate, methylcellulose, methylparaben, PEG-100 stearate, polyoxyl 40 stearate, propylene glycol, propylparaben, and purified water. Usual Dosage: Shake well. Apply to the affected areas and rub in thoroughly.

Use twice daily or as directed by a physician. Keep out of reach of children. Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature].

For lot number and expiration date, see bottle. Manufactured By Padagis, Minneapolis, MN 55427 2204954 Rev 06-25 33PA7 RC F4 Ammonium Lactate Lotion, 12% label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
47.9K
Units reimbursed last 4 qtrs
11M
Gross reimbursed last 4 qtrs
$730.9K
Avg / prescription
$15.27
Avg / unit
$0.0667
Latest quarter Q1 2026
11.1KRx
Medicaid pays / g
$0.0667
gross reimbursed
vs
NADAC / g
$0.0732
acquisition cost
=
Spread
−$0.0065
-9% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
14% FFS 86% MCO
Fee-for-service · 6,607 Rx Managed care · 41,256 Rx
State Medicaid map
Alaska: no data reported AK Maine: 46,125 units · 3,306 per 100k residents ME Washington: 52,825 units · 676 per 100k residents WA Idaho: no data reported ID Montana: 2,475 units · 219 per 100k residents MT North Dakota: no data reported ND Minnesota: 77,178 units · 1,345 per 100k residents MN Wisconsin: 105,484 units · 1,785 per 100k residents WI Michigan: 1,735,579 units · 17,292 per 100k residents MI New York: 9,450 units · 48.3 per 100k residents NY Vermont: no data reported VT New Hampshire: 2,925 units · 209 per 100k residents NH Oregon: 3,025 units · 71.5 per 100k residents OR Nevada: 410,031 units · 12,838 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 22,051 units · 688 per 100k residents IA Illinois: 244,547 units · 1,949 per 100k residents IL Indiana: 210,604 units · 3,069 per 100k residents IN Ohio: 731,167 units · 6,204 per 100k residents OH Pennsylvania: 869,819 units · 6,711 per 100k residents PA New Jersey: 1,270,437 units · 13,675 per 100k residents NJ Massachusetts: 348,913 units · 4,984 per 100k residents MA California: no data reported CA Utah: 11,475 units · 336 per 100k residents UT Colorado: 40,275 units · 685 per 100k residents CO Nebraska: 48,600 units · 2,457 per 100k residents NE Missouri: no data reported MO Kentucky: 154,697 units · 3,418 per 100k residents KY West Virginia: 68,850 units · 3,890 per 100k residents WV Virginia: 441,593 units · 5,066 per 100k residents VA Maryland: 391,205 units · 6,330 per 100k residents MD Connecticut: 432,900 units · 11,968 per 100k residents CT Rhode Island: 163,125 units · 14,897 per 100k residents RI Arizona: 83,251 units · 1,120 per 100k residents AZ New Mexico: no data reported NM Kansas: 5,175 units · 176 per 100k residents KS Arkansas: 8,550 units · 279 per 100k residents AR Tennessee: 48,152 units · 676 per 100k residents TN North Carolina: 160,755 units · 1,484 per 100k residents NC South Carolina: 116,100 units · 2,161 per 100k residents SC Delaware: no data reported DE Oklahoma: 12,825 units · 316 per 100k residents OK Louisiana: 241,532 units · 5,281 per 100k residents LA Mississippi: no data reported MS Alabama: 17,850 units · 349 per 100k residents AL Georgia: 278,365 units · 2,524 per 100k residents GA D.C.: 188,984 units · 27,833 per 100k residents DC Hawaii: 71,100 units · 4,955 per 100k residents HI Texas: 682,304 units · 2,237 per 100k residents TX Florida: 1,141,002 units · 5,046 per 100k residents FL
Units reimbursed · per 100k residents
48.327,833
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 D.C. 27,833 /100k
2 Michigan 17,292 /100k
3 Rhode Island 14,897 /100k
4 New Jersey 13,675 /100k
5 Nevada 12,838 /100k
6 Connecticut 11,968 /100k
7 Pennsylvania 6,711 /100k
8 Maryland 6,330 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
225 g this page45802-0419-54 47,863 Rx · $730,899
400 g45802-0419-26 43,996 Rx · $1,083,692
Drug total (last 4 qtrs): 91,859 Rx · 28,447,338 units · $1,814,591 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Ammonium Lactate — the program that covers self-administered drugs. 3 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Ammonium Lactate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$7.57M
Claims incl. refills
359.4K
Beneficiaries
250K
Spend / beneficiary
$30.29
Spend / claim
$21.07
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 45802-0410-59 · Padagis 45802-0423-35 · Padagis →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.